Transcend Therapeutics

📍 New York, United States🗓 Founded 2021👥 30 employees💰 Last funded Nov 2025
Biotechnology Research🌐 transcendtherapeutics.com
Website LinkedIn
Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Our leadership team has made pivotal contributions to 13 FDA approvals (including recent MDD approval), $3.5B in M&A, and significant public company value creation. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and access.
8
Total investors
6
Early stage
2
Mid stage
0
Late stage
2021
Founded

Investors

8 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
7
United Kingdom
1
Investor activity2020–2025 · investors recorded per year
20202202132022120252
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Transcend Therapeutics?
Transcend Therapeutics has 8 investors on record on gritt.io, including 6 early-stage backers, 2 mid-stage.
When did Transcend Therapeutics last raise funding?
The most recent investment in Transcend Therapeutics recorded on gritt.io was in November 2025.
When was Transcend Therapeutics founded?
Transcend Therapeutics was founded in 2021.
What industry is Transcend Therapeutics in?
Transcend Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Transcend Therapeutics based?
Transcend Therapeutics is headquartered in New York, United States.